-
Are Psychedelics A Threat To Alcohol And Tobacco Industries? A Glance At Thriving Advances
Tuesday, April 4, 2023 - 2:42pm | 671As the attachment to both tobacco and alcohol is deeply rooted and likely intertwined with other human and societal factors, it is evident these behaviors are complex to analyze. And yet, the near future seems to hold hope for those ready and willing to disengage from these...
-
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead
Wednesday, February 1, 2023 - 11:51am | 609(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains Next-Generation Psychedelics, MEAI - What And When Clearmind...
-
Psyched: VC Fund Invests $50M In Psychedelics, Musk's 'Exploratory Journeys', Native American Use Of Peyote And More
Friday, October 14, 2022 - 5:57pm | 1605Palo Santo Closes $50M Investment Fund Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund. “Against the backdrop of a growing global mental health crisis, our mission is to...
-
Can Ketamine Treat Alcohol Addiction? The Awakn Approach
Monday, October 10, 2022 - 10:24am | 893(Part three of a four-part series) As for ketamine-assisted therapy, biotech psychedelics company Awakn Life Sciences (OTC: AWAKNF) offers two distinct protocols. One is called KARE (Ketamine in the Reduction of Alcoholic Relapse) and is specific to alcohol use disorder, while the other, KAP (...
-
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: What Science Is Saying
Thursday, September 22, 2022 - 10:28am | 896(Part three of a four-part series) Despite ongoing legal setbacks, psychedelics research has reemerged and it is proving that psilocybin reduces brain connections within the usual networks while amplifying links between less connected areas. Alterations on sustained networks seem to...
-
Addex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use Disorder
Tuesday, February 16, 2021 - 1:52pm | 204Addex Therapeutics (NASDAQ: ADXN) has announced that a review published in Alcohol and Alcoholism suggests that positive allosteric modulators (PAMs) of the gamma-aminobutyric acid B (GABAB) receptor could potentially offer a new treatment option for patients with severe alcohol use...